Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Teva Pharma Japan to Temporarily Suspend Supply of Elsamet Combination Tablets
November 28, 2013
- Azilva Tops Physician “Mind Share” Ranking in GP, HP Markets in October: New Survey
November 27, 2013
- Sanofi to Revamp Sales Organization, 5 Units to Come Under Direct Control of President
November 27, 2013
- Santen’s Anti-Allergic Eye Drops Alesion Goes on Sale
November 27, 2013
- Eisai to Take Over Marketing Rights for Gliadel from Nobelpharma
November 27, 2013
- CHMP Recommends Approval of Otsuka’s Delamanid for Treatment of MDR-TB
November 27, 2013
- IFN-Free Hepatitis C Drugs Could Hit Pharmacy Shelves in 2014, New Option for Elderly Patients
November 26, 2013
- Alfresa Pharma Gets Additional Indication for Anafranil
November 26, 2013
- Farmorubicin Approved for Additional Dosage and Administration for Hepatic Cancer: Pfizer Japan
November 26, 2013
- GSK’s Paxil Granted Japan’s 1st PTSD Indication
November 26, 2013
- Japan’s 1st Acetaminophen IV Injection Now Available
November 26, 2013
- Chugai’s Avastin Approved for Ovarian Cancer Treatment
November 25, 2013
- AZ Aims to Maintain Presence in Oncology Field Via Partnerships until Launch of New Drugs
November 25, 2013
- Preminent Generics of 30-Plus Firms Likely to Carry “Losarhyd” Brand; Unified Trade Names Logged for 4 More Combination Generics
November 25, 2013
- Kyowa Kirin Launches New PIII Trial for Istradefylline
November 25, 2013
- ASKA Pharmaceutical Plans to Launch Generic Version of Takeda’s Leuplin, Aims for 20% Market Share
November 25, 2013
- Once-Monthly Injectable Abilify Maintena Approved in Europe: Otsuka
November 25, 2013
- Domestic Ethical Drug Market Estimated to Reach 9,617.7 Billion Yen in 2020: Fuji Keizai
November 22, 2013
- Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases
November 22, 2013
- Mid-sized Foreign Drug Makers Eying Full-scale Entry into Japanese Market Encouraged by Favorable Changes in Market Environment; Marketing Systems May Be Key to Success
November 22, 2013
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…